EADV 2022: Risankizumab Demonstrates Long-Term Effectiveness in Psoriatic Arthritis
More patients receiving risankizumab versus placebo achieved ACR20 and PASI 90 at 100 weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.